Professor Zhi Xiuyi commented that the first batch of lung cancer blood methylized kit brought a new turnaround for early screening of lung cancer

On July 1, the "Top Ten Progress in the Cancer Field of the Public Public Most Incurities in 2021" was launched in "I do practical practice activities for the masses · Healthy Chinese Oncology Prevention and Control (2022-2023) and" Tumor's Things "column launched The launching ceremony was officially released.

(The above comments are from Professor Zhixiuyi Professor China Anti -Cancer Association Popular Science Propaganda Department, Chief Expert of Chestning Department of Xuanwu Hospital of Xuanwu Hospital of Capital Medical University)

According to the World Health Organization Cancer Research Agency (IARC) 2020 global cancer epidemic data, the incidence and mortality of lung cancer ranked first in my country. The disease of lung cancer is generally not obvious. When symptoms occur, the best period of treatment has been missed when symptoms occur. Early screening of lung cancer has become the focus of major medical institutions for medical institutions.

In recent years, low -dose spiral CT testing combined with artificial intelligence technology liquid biopsy multi -dimensional evaluation, which constitutes a early section of lung cancer system in the new period. Pulmonary blood cancer testing is based on liquid biopsy technology, which can effectively achieve early auxiliary diagnosis of lung cancer.

The successful approval of the first lung cancer blood methylized kit, whether it is the clinical application of the high -risk group of lung cancer or the liquid biopsy technology, is a good news.

- END -